Connect with us

Hi, what are you looking for?

Jewish Business News

Business

Perrigo CEO will discuss deal with Mylan at right price

Joseph C. Papa - PERRIGO - PR

Perrigo Company (NYSE:PRGO; TASE:PRGO) CEO Joseph Papa is ready to talk with Mylan N.V. (MYL) about its takeover bid, but at a higher price. The rival drugmaker’s present bid is nowhere near there.

Perrigo last month rejected Mylan’s offer of $75 in cash and 2.3 Mylan shares for each Perrigo share, which had a value of about $32.7 billion.

At the same time, Teva Pharmaceutical Industries Ltd. (NYSE: TEVA; TASE: TEVA) has offered to acquire Mylan for more than $40 billion on condition that the Mylan-Perrigo deal does not go ahead.

“We’re pretty far apart, ” Perrigo CEO Joseph Papa said Monday at an investor meeting hosted by UBS AG in New York, where he gave a presentation and spoke to investors during a smaller session. “We believe they have substantially undervalued the company.”

UBS published a summary of Papa’s speech in which he said that Mylan “substantially undervalued the company.” In addition, he said that Mylan’s rate of growth and profit multiple would lead to a dilution for Perrigo’s shareholders. Papa added that the ROIC (return on investment capital) from the deal was not attractive and that if Perrigo decided to consider Mylan’s offer, he would also discuss the matter with other potential buyers to achieve the best returns for shareholders.

UBS said that in the long term Perrigo could achieve organic growth of 5-10% while continuing to seek non-organic growth opportunities.

Mylan has said it plans to go directly to Perrigo’s shareholders with an offer. That could happen by Sept. 14, Papa said at the conference. Perrigo doesn’t plan to use a poison pill to try to block such an offer.

Click to comment

Leave a Reply

Your email address will not be published. Required fields are marked *

This site uses Akismet to reduce spam. Learn how your comment data is processed.

Newsletter

Advertisement

You May Also Like

World News

In the 15th Nov 2015 edition of Israel’s good news, the highlights include:   ·         A new Israeli treatment brings hope to relapsed leukemia...

empty

The contract signed between the Israeli government and Pfizer shows clearly and unequivocally that this is a clinical study on humans - The agreement...

Travel

After two decades without a rating system in Israel, at the end of 2012 an international tender for hotel rating was published.  Invited to place bids...

VC, Investments

You may not become a millionaire, but there is a lot to learn from George Soros.

Advertisement
cialis cialis satış